Predictors for Mortality in Patients with Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis: A Study of 398 Chinese Patients

REFERENCES

1. 1.↵
   1. Jennette JC,
   2. Falk RJ,
   3. Bacon PA,
   4. Basu N,
   5. Cid MC,
   6. Ferrario F,
   7. et al.

   2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Walton EW

   . Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J 1958;2:265–70.

   OpenUrlFREE Full Text
3. 3.↵
   1. Jayne D,
   2. Rasmussen N,
   3. Andrassy K,
   4. Bacon P,
   5. Tervaert JW,
   6. Dadoniené J,
   7. et al.

   A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Flossmann O,
   2. Berden A,
   3. de Groot K,
   4. Hagen C,
   5. Harper L,
   6. Heijl C,
   7. et al.

   Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488–94.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Little MA,
   2. Nightingale P,
   3. Verburgh CA,
   4. Hauser T,
   5. De Groot K,
   6. Savage C,
   7. et al.

   Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036–43.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Hogan SL,
   2. Nachman PH,
   3. Wilkman AS,
   4. Jennette JC,
   5. Falk RJ

   . Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23–32.

   OpenUrlAbstract
7. 7.↵
   1. Booth AD,
   2. Almond MK,
   3. Burns A,
   4. Ellis P,
   5. Gaskin G,
   6. Neild GH,
   7. et al.

   Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 2003;41:776–84.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Harper L,
   2. Savage CO

   . ANCA-associated renal vasculitis at the end of the twentieth century — A disease of older patients. Rheumatology 2005;44:495–501.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Chen M,
   2. Yu F,
   3. Zhang Y,
   4. Zou WZ,
   5. Zhao MH,
   6. Wang HY

   . Characteristics of Chinese patients with Wegener’s granulomatosis with anti-myeloperoxidase. Kidney Int 2005;68:2225–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Watts RA,
    2. Scott DG

    . Epidemiology of the vasculitides. Semin Respir Crit Care Med 2004;25:455–64.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Watts RA,
    2. Gonzalez-Gay MA,
    3. Lane SE,
    4. Garcia-Porrua C,
    5. Bentham G,
    6. Scott DG

    . Geoepidemiology of systemic vasculitis: Comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001;60:170–2.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Mahr A,
    2. Guillevin L,
    3. Poissonnet M,
    4. Ayme S

    . Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: A capture–recapture estimate. Arthritis Rheum 2004;51:92–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Li ZY,
    2. Gou SJ,
    3. Chen M,
    4. Zhao MH

    . Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: A study of 89 cases in a single Chinese center. Semin Arthritis Rheum 2013;42:515–21.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Abril A,
    2. Calamia KT,
    3. Cohen MD

    . The Churg Strauss syndrome (allergic granulomatous angiitis): Review and update. Semin Arthritis Rheum 2003;33:106–14.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Zhao MH,
    2. Lockwood CM

    . A comprehensive method to purify three major ANCA antigens: Proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods 1996;197:121–30.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Luqmani RA,
    2. Bacon PA,
    3. Moots RJ,
    4. Janssen BA,
    5. Pall A,
    6. Emery P,
    7. et al.

    Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671–8.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Charlier C,
    2. Henegar C,
    3. Launay O,
    4. Pagnoux C,
    5. Berezné A,
    6. Bienvenu B,
    7. et al.

    Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 2009;68:658–63.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Suppiah R,
    2. Judge A,
    3. Batra R,
    4. Flossmann O,
    5. Harper L,
    6. Höglund P

    . A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res 2011;63:588–96.

    OpenUrlCrossRef
19. 19.↵
    1. Kalbfleisch JD,
    2. Prentice RL

    . The statistical analysis of failure time data. Hoboken, NJ: John Wiley & Sons;2011:196–208.
20. 20.↵
    1. Fisher LD,
    2. Lin DY

    . Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Pub Health 1999;20:145–57.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Guillevin L,
    2. Pagnoux C,
    3. Seror R,
    4. Mahr A,
    5. Mouthon L,
    6. Le Toumelin P

    . Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 2011;90:19–27.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Millet A,
    2. Pederzoli-Ribeil M,
    3. Guillevin L,
    4. Witko-Sarsat V,
    5. Mouthon L

    . Antineutrophil cytoplasmic antibody-associated vasculitides: Is it time to split up the group? Ann Rheum Dis 2013;72:1273–9.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Chen M,
    2. Yu F,
    3. Zhang Y,
    4. Zhao MH

    . Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine 2008;87:203–9.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Hauer HA,
    2. Bajema IM,
    3. van Houwelingen HC,
    4. Ferrario F,
    5. Noël LH,
    6. Waldherr R,
    7. et al.

    Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int 2002;61:80–9.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Bourgarit A,
    2. Le Toumelin P,
    3. Pagnoux C,
    4. Cohen P,
    5. Mahr A,
    6. Le Guern V,
    7. et al.

    Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: A retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine 2005;84:323–30.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Goupil R,
    2. Brachemi S,
    3. Nadeau-Fredette AC,
    4. Déziel C,
    5. Troyanov Y,
    6. Lavergne V,
    7. et al.

    Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013;8:416–23.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Dixon WG,
    2. Abrahamowicz M,
    3. Beauchamp ME,
    4. Ray DW,
    5. Bernatsky S,
    6. Suissa S,
    7. et al.

    Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: A nested case-control analysis. Ann Rheum Dis 2012;71:1128–33.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Morton M,
    2. Edmonds S,
    3. Doherty AM,
    4. Dhaygude A,
    5. Helbert M,
    6. Venning M

    . Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement. Rheumatol Int 2012;32:3373–82.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Mukhtyar C,
    2. Guillevin L,
    3. Cid MC,
    4. Dasgupta B,
    5. de Groot K,
    6. Gross W,
    7. et al.

    EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310–7.

    OpenUrlAbstract/FREE Full Text